vericel
reports
record
third
quarter
revenues
net
income
total
net
revenues
million
net
income
million
conference
call
today
eastern
time
cambridge
globe
newswire
vericel
corporation
nasdaq
vcel
leader
advanced
therapies
sports
medicine
severe
burn
care
markets
today
reported
financial
results
business
highlights
third
quarter
ended
september
third
quarter
financial
highlights
total
net
revenues
million
compared
million
third
quarter
maci
net
revenue
million
epicel
net
revenue
million
nexobrid
revenue
million
related
biomedical
advanced
research
development
authority
barda
procurement
national
response
preparedness
net
revenue
million
epicel
net
revenue
million
nexobrid
revenue
million
related
biomedical
advanced
research
development
authority
barda
procurement
national
response
preparedness
gross
margin
compared
gross
margin
third
quarter
net
income
million
per
share
compared
million
per
share
third
quarter
adjusted
ebitda
million
compared
million
third
quarter
operating
cash
flow
million
cash
investments
million
september
compared
million
december
debt
business
highlights
updates
reported
record
third
quarter
maci
revenue
total
revenues
second
highest
quarterly
epicel
revenue
history
achieved
growth
maci
revenue
implants
biopsies
third
quarter
including
record
monthly
high
biopsies
september
announced
first
delivery
nexobrid
barda
emergency
response
preparedness
announced
fda
accepted
review
biologics
license
application
nexobrid
treatment
severe
thermal
burns
pdufa
goal
date
june
company
executed
exceedingly
well
third
quarter
generated
stronger
expected
financial
results
drove
strong
commercial
performance
maci
epicel
achieved
important
milestones
towards
goal
obtaining
marketing
approval
nexobrid
united
states
said
nick
colangelo
president
ceo
vericel
third
quarter
results
demonstrated
strength
business
across
several
measures
uncertainties
related
remain
highly
confident
underlying
fundamentals
business
remain
track
deliver
strong
revenue
profit
growth
years
third
quarter
results
total
net
revenues
quarter
ended
september
increased
million
compared
million
third
quarter
total
net
product
revenues
quarter
included
million
maci
autologous
cultured
chondrocytes
porcine
collagen
membrane
net
revenue
million
epicel
cultured
epidermal
autografts
net
revenue
compared
million
maci
net
revenue
million
epicel
net
revenue
respectively
third
quarter
million
revenue
related
procurement
nexobrid
concentrate
proteolytic
enzymes
enriched
bromelain
barda
emergency
response
preparedness
gross
profit
quarter
ended
september
million
net
revenues
compared
million
net
revenues
third
quarter
total
operating
expenses
quarter
ended
september
million
compared
million
period
increase
primarily
driven
incremental
employee
expenses
related
maci
sales
force
expansion
vericel
net
income
quarter
ended
september
million
per
share
compared
million
per
share
third
quarter
adjusted
ebitda
million
quarter
ended
september
compared
million
third
quarter
table
reconciling
measures
included
press
release
reference
september
company
million
cash
investments
compared
million
december
debt
conference
call
information
today
conference
call
available
live
eastern
time
accessed
investor
relations
section
vericel
website
http
slide
presentation
highlights
today
conference
call
available
webcast
investor
relations
section
vericel
website
please
access
site
least
minutes
prior
scheduled
start
time
order
download
required
audio
software
necessary
participate
live
call
telephone
please
call
reference
vericel
corporation
investor
conference
call
calling
outside
please
use
international
phone
number
unable
participate
live
call
webcast
available
http
november
replay
call
also
available
edt
november
calling
outside
calling
conference
id
vericel
corporation
vericel
leader
advanced
therapies
sports
medicine
severe
burn
care
markets
company
markets
two
cell
therapy
products
united
states
maci
autologous
cultured
chondrocytes
porcine
collagen
membrane
autologous
cellularized
scaffold
product
indicated
repair
symptomatic
single
multiple
cartilage
defects
knee
without
bone
involvement
adults
epicel
cultured
epidermal
autografts
permanent
skin
replacement
treatment
patients
deep
dermal
burns
greater
equal
total
body
surface
area
company
also
holds
exclusive
license
north
american
rights
nexobrid
biological
orphan
product
debridement
severe
thermal
burns
information
please
visit
company
website
gaap
measures
vericel
reported
earnings
prepared
accordance
generally
accepted
accounting
principles
united
states
gaap
represent
earnings
reported
securities
exchange
commission
vericel
provided
release
certain
financial
information
prepared
accordance
gaap
vericel
management
believes
adjusted
ebitda
described
release
includes
adjustments
specific
items
generally
indicative
core
operations
provides
additional
information
useful
investors
understanding
vericel
underlying
performance
business
performance
trends
helps
facilitate
comparisons
comparisons
financial
measures
companies
vericel
industry
however
financial
measures
vericel
uses
may
differ
measures
companies
may
use
financial
measures
required
uniformly
applied
audited
considered
isolation
substitutes
results
prepared
accordance
gaap
registered
trademarks
vericel
corporation
registered
trademark
mediwound
used
license
vericel
corporation
vericel
corporation
rights
reserved
statements
vericel
cautions
statements
statements
historical
fact
included
press
release
address
activities
events
developments
expect
believe
anticipate
may
occur
future
statements
although
believe
reasonable
basis
statements
contained
herein
based
current
expectations
future
events
affecting
us
subject
risks
assumptions
uncertainties
factors
relating
operations
business
environment
difficult
predict
many
beyond
control
actual
results
may
differ
materially
expressed
implied
statements
press
release
statements
often
always
made
use
words
phrases
anticipates
intends
estimates
plans
expects
continues
believe
guidance
outlook
target
future
potential
goals
similar
words
phrases
future
conditional
verbs
would
could
may
similar
expressions
among
factors
could
cause
actual
results
differ
materially
set
forth
statements
include
limited
uncertainties
associated
expectations
regarding
future
revenues
growth
revenues
market
penetration
maci
epicel
growth
profit
gross
margins
operating
margins
ability
achieve
sustain
profitability
contributions
adjusted
ebitda
expected
target
surgeon
audience
potential
fluctuations
sales
volumes
results
operations
course
year
timing
conduct
clinical
trial
product
development
activities
timing
likelihood
regulatory
approvals
estimate
commercial
growth
potential
products
product
candidates
availability
funding
biomedical
research
development
authority
agreement
mediwound
use
connection
nexobrid
development
activities
competitive
developments
changes
third
party
coverage
reimbursement
ability
supply
meet
customer
demand
products
impacts
pandemic
business
economy
generally
respect
currently
unable
reasonably
estimate
specific
extent
duration
impact
outbreak
business
financial
operating
results
also
unable
predict
whether
outbreak
cause
state
local
governments
impose
future
restrictions
performance
elective
surgical
procedures
pace
restrictions
may
lifted
imposed
willingness
ability
patients
seek
treatment
availability
physicians
treatment
prioritizations
impact
outbreak
overall
healthcare
infrastructure
disruptions
potential
disruptions
include
restrictions
ability
company
personnel
travel
access
customers
training
promotion
case
support
delays
product
development
efforts
additional
quarantines
requirements
shelter
home
incremental
mitigation
efforts
may
impact
ability
source
supplies
operations
ability
capacity
manufacture
sell
support
use
products
respect
fda
review
pending
nexobrid
biologics
license
application
pandemic
may
impact
fda
response
times
regulatory
submissions
ability
monitor
clinical
trials
conduct
necessary
reviews
inspections
may
result
timelines
materially
delayed
could
affect
development
ultimate
commercialization
nexobrid
total
impact
disruptions
could
material
impact
company
financial
condition
cash
flows
results
operations
significant
factors
discussed
greater
detail
vericel
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
february
vericel
quarterly
report
form
quarter
ended
september
filed
sec
november
filings
sec
statements
reflect
views
date
hereof
vericel
assume
specifically
disclaims
obligation
update
statements
reflect
change
views
events
circumstances
occur
date
release
except
required
law
investor
contacts
lee
stern
solebury
trout
lstern
vericel
corporation
condensed
consolidated
balance
sheets
unaudited
amounts
thousands
september
december
assets
current
assets
cash
cash
equivalents
investments
accounts
receivable
net
allowance
doubtful
accounts
respectively
inventory
current
assets
total
current
assets
property
equipment
net
restricted
cash
leased
assets
investments
total
assets
liabilities
shareholders
equity
current
liabilities
accounts
payable
accrued
expenses
current
portion
operating
lease
liabilities
liabilities
total
current
liabilities
operating
lease
liabilities
liabilities
total
liabilities
commitments
contingencies
shareholders
equity
common
stock
par
value
shares
authorized
shares
issued
outstanding
respectively
comprehensive
gain
accumulated
deficit
total
shareholders
equity
total
liabilities
shareholders
equity
vericel
corporation
condensed
consolidated
statements
operations
unaudited
amounts
thousands
except
per
share
amounts
three
months
ended
september
nine
months
ended
september
product
sales
net
revenue
total
revenue
cost
product
sales
gross
profit
research
development
selling
general
administrative
total
operating
expenses
income
loss
operations
income
expense
interest
income
interest
expense
income
expense
total
income
net
income
loss
net
income
loss
per
share
attributable
common
shareholders
basic
weighted
average
number
common
shares
outstanding
basic
net
income
loss
per
share
attributable
common
shareholders
diluted
weighted
average
number
common
shares
outstanding
diluted
reconciliation
reported
net
income
loss
gaap
adjusted
ebitda
measure
unaudited
three
months
ended
september
nine
months
ended
september
thousands
net
income
loss
license
agreement
purchase
stock
compensation
expense
depreciation
amortization
net
interest
income
adjusted
ebitda
